Aromatase Inhibitors versus Tamoxifen for Pre-Menopausal Women Diagnosed With Early-Stage, Hormone Receptor-Positive Disease

Summary: Dr. Jeremy Braybrooke is a consultant medical oncologist and clinical lead for oncology at University Hospitals Bristol, as well as a senior clinical research fellow at the University of Oxford. Rosie Bradley is a medical statistician in the Clinical Trial Service Unit at the University of Oxford. At the 2021 San Antonio Breast Cancer Symposium, Rosie presented the results of their meta-analysis of four studies looking at effectiveness of aromatase inhibitors compared to tamoxifen in pre-menopausal women diagnosed with early-stage, hormone receptor-positive disease. Listen to the episode to hear them explain: the results of the study, showing that an aromatase inhibitor and ovarian suppression reduced recurrence risk more than tamoxifen, but didn’t lead to better overall survival the side effects of aromatase inhibitors and tamoxifen how Dr. Braybrooke is advising his pre-menopausal patients diagnosed with early-stage, hormone receptor-positive disease Running time: 14:19